Fig. 1: ACTHIVE-001 trial profile and vaccination schedule. | Nature Communications

Fig. 1: ACTHIVE-001 trial profile and vaccination schedule.

From: HIV-1 envelope trimer vaccine induces sex-associated differences in antibody responses: a phase 1 clinical trial

Fig. 1: ACTHIVE-001 trial profile and vaccination schedule.

A Modified intention-to-treat cohort: participants who received at least one vaccination (N = 24). Per-protocol cohort: participants who received all three vaccinations and completed at least the 48 weeks follow-up visit (N = 23). B Participants received intramuscular (i.m.) vaccinations at baseline, eight weeks and 24 weeks. Dosing between vaccine groups differs at 24 weeks, as indicated. Blood samples were collected as indicated in black. Green bars represent leukapheresis procedures. Orange bars indicate lymph node fine needle aspirations in addition to blood sampling.

Back to article page